Company news
Moleculin Biotech, Inc. (NASDAQ:MBRX) news
Moleculin Biotech, Inc. news releases on 6ix. Latest, Sep 9, 2020: Moleculin Announces Successful Completion of Pre-IND Meeting with the FDA
Press releases — page 5
Moleculin Announces Successful Completion of Pre-IND Meeting with the FDA
September 8, 2020
Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June 30, 2020
August 11, 2020
Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate
July 14, 2020
Moleculin Provides Update on Annamycin Clinical Development
July 1, 2020
Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases
June 24, 2020
Moleculin Announces Confirmatory In Vitro Analysis of WP1122
June 15, 2020
Moleculin Announces Submission to Expand Clinical Sites in European AML Trial
June 3, 2020
Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment
June 1, 2020
Moleculin Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020
May 26, 2020
Moleculin Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 15, 2020
May 7, 2020
Moleculin Approved to Accelerate European Clinical Trial
April 27, 2020
Moleculin Announces Head of NIAID Antiviral Drug Discovery and Development Center Joins COVID-19 Drug Development Team
April 21, 2020
Moleculin Announces Agreement with ImQuest Biosciences to Expand Coronavirus Testing
April 19, 2020
Moleculin Announces Leading Virologist Joins Development Team
April 14, 2020
Moleculin Announces Active Compound in WP1122 Reduces Coronavirus Replication In Vitro by 100%
April 7, 2020
Moleculin Announces Additional Positive Safety Data in EU AML Trial
April 1, 2020
Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate
March 19, 2020
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2019
March 18, 2020
Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus
March 16, 2020
Moleculin Announces Dr. Hongbo Zhai Joins Science Advisory Board
March 9, 2020
Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date
February 19, 2020
Moleculin Announces $6.0 Million Registered Direct Offering
February 5, 2020
Moleculin to Seek Accelerated FDA Approval and Plans for Pivotal Phase 2 AML Trial
February 4, 2020
Moleculin Announces Successful Completion of US Phase 1 AML Trial of Annamycin
February 2, 2020
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
December 3, 2019
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
November 18, 2019
Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer
November 12, 2019
Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial
November 11, 2019
Moleculin Announces New Data Confirms Anti-tumor Efficacy of Annamycin in Both Human and Murine AML Models
October 28, 2019
Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications
October 21, 2019
Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery
September 15, 2019
Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2019
August 15, 2019
Moleculin Announces Completion of Lymphoma Trial Enrollment
August 12, 2019
Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models
August 5, 2019
Moleculin Announces Annamycin in Acute Myeloid Leukemia in Poland Advances to 3rd Cohort
July 17, 2019
Moleculin Files for New Patents for Annamycin After Receiving FDA Approval of Fast Track Designation
July 9, 2019
Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2019
May 13, 2019
Moleculin Announces Conference Call to Discuss Significant Discovery For Lung Cancer and FDA Activity on Wednesday, April 24, 2019
April 21, 2019
Moleculin Receives FDA Approval of Fast Track Designation for Annamycin
April 17, 2019
Moleculin Announces Significant Discovery in Lung Cancer Models
April 16, 2019
Moleculin Announces Agreement with Emory University to Conduct Pediatric Brain Tumor Trial
April 10, 2019
Moleculin Announces Successful Expansion of its Leukemia Drug Program
April 8, 2019
Moleculin Announces Preclinical Pancreatic Cancer Data Presented at American Association for Cancer Research Annual Meeting
April 2, 2019